Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael T. Chin
Tufts Medical Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
TransCellular Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Equity Interest - Non-publicly traded entity - Dr. Chin owns (b)(4) of the stock of the company which currently has an estimated value of (b)(4). His prior institution, University of Washington licensed four intellectual property assets that were developed in the academic laboratory at the University of Washington to the company. There has not been any income received by Dr. Chin related to the intellectual property assets licensed to him company.
The research in his academic laboratory at Tufts Medical Center that is funded by this NIH grant is focused on understanding the mechanisms of tafazzin deficiency in Barth Syndrome and addressing whether an enzyme replacement therapy can improve heart and skeletal muscle improvement and can improve neutropenia in these patients. The company is developing recombinant tafazzin enzyme replacement therapeutics for Barth syndrome and other disorders. As such, the work in the company is related to the research performed in the laboratory.
Intracellular mitochondrial enzyme replacement therapy for heart and skeletalmyopathy in Barth Syndrome
Project Narrative Barth Syndrome is a genetic disorder characterized by muscle and white blood cell dysfunction that results from deficiency of an enzyme called tafazzin. Developing an enzyme replacement reagent and understanding its distribution in tissues and effects on muscle and blood will have important implications for treating this disorder in human populations.
Filed on October 17, 2018.
Tell us what you know about Michael T. Chin's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Michael T. Chin filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michael Chin | Tufts Medical Center | Conflict of Interest | TransCellular Therapeutics | $0 - $4,999 |
| Michael Chin | Tufts Medical Center | Conflict of Interest | TransCellular Therapeutics | $0 - $4,999 |
| Michael T. Chin | Tufts Medical Center | Conflict of Interest | TransCellular Therapeutics | $0 - $4,999 |
| Michael Chin | University of Washington | Conflict of Interest | TransCellular Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.